What does semaglutide do in the body?

Semaglutide activates GLP-1 receptors in several tissues. In the pancreas, it amplifies glucose-dependent insulin secretion and reduces glucagon when glucose is elevated. It also delays the early phase of stomach emptying and changes signalling in neural networks involved in satiety and meal termination. These are coordinated effects from one receptor target, not separate active ingredients.

How does semaglutide affect insulin?

Semaglutide amplifies insulin release when glucose is elevated. GLP-1 receptor activation raises cyclic AMP inside pancreatic beta cells, strengthening the calcium-dependent release of stored insulin. The process is described as glucose-dependent because it builds on a glucose-driven signal. That does not make hypoglycemia impossible, especially when insulin or certain other glucose-lowering medicines are also involved.

Does semaglutide slow stomach emptying?

Semaglutide delays the early phase of gastric emptying. In a 30-person crossover study, the first-hour measure was 27% lower with semaglutide than placebo, while the overall five-hour measure was not statistically different. That supports a front-loaded delay rather than the idea that digestion stops. The effect can slow how quickly meal-derived glucose enters circulation.

How does semaglutide reduce appetite?

Semaglutide reinforces GLP-1 receptor signalling in networks involved in satiety, meal termination and food reward. Preclinical work maps activity across connected brain regions, while human trials measure lower energy intake and changes in hunger or food preoccupation. Stomach emptying may contribute to fullness, but central signalling is a separate and important part of the mechanism.

Why does semaglutide last about a week?

Semaglutide combines resistance to DPP-4 breakdown with a C18 fatty-diacid side chain that binds reversibly to albumin. Albumin serves as a circulating reservoir and reduces rapid kidney clearance. A human pharmacology study measured a 165-hour half-life, which is just under seven days. The long duration comes from both structural features working together.

Is semaglutide the same as insulin?

Semaglutide is not insulin. It is a GLP-1 receptor agonist that amplifies the body's glucose-dependent insulin response and affects glucagon, early gastric emptying and satiety signalling. Insulin directly replaces or supplements the hormone that moves glucose into cells. Because the mechanisms differ, using the medicines together changes the safety and monitoring considerations.

How Does Semaglutide Work? Four Effects Explained

How does semaglutide work? It activates the glucagon-like peptide-1, or GLP-1, receptor. That one signal has four connected effects: it amplifies insulin release when glucose is elevated, reduces glucagon during higher-glucose states, slows the first phase of stomach emptying, and reinforces satiety signalling in the brain. A C18 fatty-diacid side chain also helps the peptide remain in circulation, producing a half-life of about one week.

Those effects overlap, but they are not interchangeable. Semaglutide does not simply "make more insulin," and appetite change is not just food remaining in the stomach longer.

How does semaglutide work at the receptor?

GLP-1 is a hormone released from the gut after nutrients arrive. Its receptor appears in several tissues, including pancreatic islet cells and specific regions involved in appetite regulation. Natural GLP-1 is short-lived. Semaglutide is a GLP-1 analogue: its amino-acid sequence is engineered to resist rapid enzymatic breakdown while still fitting and activating the GLP-1 receptor.

The receptor is a G-protein-coupled receptor. When semaglutide binds, it raises cyclic AMP inside responsive cells. Cyclic AMP is a messenger, not the endpoint. In a pancreatic beta cell, for example, it strengthens the calcium-dependent machinery that releases stored insulin. In neural circuits, the same receptor class changes activity in networks involved in meal termination and food reward. The tissue receiving the signal determines the downstream effect.

The pancreas: an amplifier for glucose signals

In beta cells, glucose metabolism starts the insulin-release process. GLP-1 receptor activation amplifies it. That is what "glucose-dependent insulin secretion" means: semaglutide strengthens a response that is already being driven by glucose rather than switching insulin release on at full force regardless of glucose level.

A randomized study in 75 adults with type 2 diabetes makes that distinction concrete. After 12 weeks, first-phase insulin secretion was 3.02 times and second-phase secretion 2.10 times the placebo response. The graded-glucose test also found that insulin secretion rose as glucose exposure rose (Kapitza et al., Diabetologia 2017).

The pancreatic signal also reduces glucagon when glucose is elevated. Glucagon normally tells the liver to release more glucose. In the same trial, fasting, post-meal and 24-hour glucagon responses were lower with semaglutide than with placebo. Together, more appropriately timed insulin and less glucagon reduce two opposing sources of elevated blood glucose.

Glucose-dependent does not mean hypoglycemia is impossible. The risk picture changes when semaglutide is combined with insulin or medicines that drive insulin release through a different mechanism. That distinction belongs in an individualized medication review; semaglutide side effects and interactions covers the broader safety picture.

The stomach: a delay in the first hour

Semaglutide slows early gastric emptying, so nutrients can enter the small intestine and bloodstream more gradually after a meal. The most precise evidence is narrower than the common claim that it simply "stops digestion."

In a randomized crossover study of 30 adults with obesity, first-hour gastric-emptying exposure was 27% lower with semaglutide than with placebo. Over the full five-hour measurement, overall emptying was not statistically different (Hjerpsted et al., Diabetes, Obesity and Metabolism 2018). The supported conclusion is an early delay, not that the stomach remains inactive all day.

That early delay can soften the speed of post-meal glucose entry. It may also contribute to fullness, but it does not fully explain appetite effects: semaglutide acts on GLP-1 receptor pathways beyond the stomach.

The brain: satiety and meal termination

Satiety is the signal that a meal has been sufficient. Semaglutide appears to reinforce that signal through accessible GLP-1 receptor populations and connected neural networks. In rodents, researchers found direct access to selected sites near ventricles and in the brainstem rather than broad passage across the blood-brain barrier. They recorded activation across 10 brain regions and identified a pathway associated with meal termination (Gabery et al., JCI Insight 2020). That study explains a plausible circuit, but it is preclinical evidence and should be read as such.

Human studies measure the outcome of those signals rather than tracing individual neurons. In a 60-week randomized trial of 120 adults with overweight or obesity, the semaglutide group consumed an average of 291.9 fewer calories at week 20, 240.2 fewer at week 40 and 269.5 fewer at week 60 than the placebo group during test meals (Tronieri et al., American Journal of Clinical Nutrition 2026). Subjective appetite differences were clearer at week 20 than at weeks 40 and 60, even while the measured intake difference remained. Feeling less hungry and eating less are related observations, not identical ones.

Why the C18 chain makes the signal last

A peptide that activates the right receptor is not useful for long if enzymes and filtration remove it within minutes. Semaglutide solves that problem with two important design choices. An amino-acid substitution at position 8 makes it resistant to cleavage by the enzyme DPP-4. A spacer attached at lysine 26 carries an 18-carbon fatty diacid.

That C18 chain binds reversibly to albumin, an abundant protein in blood. Albumin acts as a circulating reservoir: binding reduces rapid kidney filtration and leaves only a small unbound fraction available for clearance at a time. The semaglutide discovery paper showed that the fatty-acid and linker design increased albumin affinity while retaining GLP-1 receptor activity (Lau et al., Journal of Medicinal Chemistry 2015).

In a human pharmacology study, the measured semaglutide half-life was 165 hours, or just under seven days (Kapitza et al., Journal of Clinical Pharmacology 2015). The C18 albumin-binding strategy and resistance to DPP-4 work together; the long duration is not a property of ordinary GLP-1.

How semaglutide differs from tirzepatide

Semaglutide works through the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors, so its mechanism adds a second incretin pathway. How tirzepatide works explains that dual signal; the essential distinction here is one receptor target versus two.

What the mechanism cannot decide

A mechanism explains what happens after a molecule reaches its receptor. It cannot establish that a medication is appropriate for a particular medical history, verify the contents of an unprescribed vial, or predict one person's response. Promise provides compounded semaglutide through a prescription process; compounding describes how a specific preparation is made and dispensed, not a different receptor mechanism.

At Promise, a licensed provider reviews every request; not everyone qualifies, and whether compounded semaglutide is appropriate is a decision between the patient and that prescriber.

The useful mental model is one receptor with effects in several places: pancreatic signalling responds to glucose, early stomach emptying slows, neural satiety pathways change, and molecular engineering keeps semaglutide available for roughly a week. None of those pieces alone explains the whole response.